Serological Sciences Network Capacity Building Centers

In light of the emergence of the novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and the urgent need to mitigate the pathogen’s spread, the National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Disease (NIAID) are establishing a Serological Sciences Network of Excellence to mobilize collaborative efforts to develop serological assays of high specificity and high sensitivity for deployment to test for SARS-CoV-2 induced immune responses and to rapidly expand national serological testing capacity.